copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Specialized Therapies | HIV and Oncology | Theratechnologies Inc. Theratechnologies develops and commercializes innovative therapies The Company currently commercializes two products in the field of HIV Trogarzo® and EGRIFTA SV® are approved in the United States We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology ™
Investor Relations - Theratechnologies Inc. Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV
Theratechnologies Receives FDA Approval of Prior Approval Supplement . . . Approval of the PAS removes any regulatory requirement for discretionary product release, thereby allowing Theratechnologies to resume regular distribution of EGRIFTA SV ® The FDA also recently approved the new F8 formulation of tesamorelin for injection, which is set to replace EGRIFTA SV ® and will be marketed in the US as EGRIFTA WR ™
Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring . . . MONTREAL, May 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced two poster presentations at the 19 th Annual American Conference for the Treatment of HIV (ACTHIV 2025), taking place May 1-3 in Chicago, Ill
Corporate Presentation - theratech. com Theratechnologies believes that this measure can be a useful indicator of its operational performance and financial condition from one period to another Theratechnologies uses this non-IFRS measure to make financial, strategic and operating decisions
Form SCHEDULE 13D A for Theratechnologies INC filed 04 11 2025 THERATECHNOLOGIES INC (Name of Issuer) Common Stock (Title of Class of Securities) 88338H704 (CUSIP Number) Soleus Capital Master Fund L P 104 Field Point Road, 2nd Floor, Attn: Steven J Musumeci Greenwich, CT, 06830 (475) 208-3178 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) 04 11 2025